Jessica Sun

Positions:

Assistant Professor of Pediatrics

Pediatrics, Hematology-Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2003

University of Medicine and Dentistry of New Jersey

Pediatric Internship & Residency, Pediatrics

Duke University

Pediatric Hematology/Oncology Fellowship, Pediatrics

Duke University

Grants:

A Phase 1 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3b) inhibitor

Administered By
Pediatrics, Hematology-Oncology
Awarded By
Actuate Therapeutics
Role
Principal Investigator
Start Date
End Date

An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors (CLOVER-2)

Administered By
Pediatrics, Hematology-Oncology
Awarded By
Cellectar Biosciences, Inc.
Role
Principal Investigator
Start Date
End Date

A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Administered By
Pediatrics, Hematology-Oncology
Awarded By
Children's Hospital of Philadelphia
Role
Principal Investigator
Start Date
End Date

Publications:

Regenerative Potential of Cord Blood

MLA Citation
Sun, Jessica M., and Joanne Kurtzberg. “Regenerative Potential of Cord Blood.” Stem Cell Biology and Regenerative Medicine, Springer International Publishing, 2014, pp. 17–38. Crossref, doi:10.1007/978-3-319-06444-4_2.
URI
https://scholars.duke.edu/individual/pub1547795
Source
crossref
Published Date
Start Page
17
End Page
38
DOI
10.1007/978-3-319-06444-4_2

Motor function and safety after allogeneic cord blood and cord tissue-derived mesenchymal stromal cells in cerebral palsy: An open-label, randomized trial.

AIM: To evaluate safety and motor function after treatment with allogeneic umbilical cord blood (AlloCB) or umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in children with cerebral palsy (CP). METHOD: Ninety-one children (52 males, 39 females; median age 3 years 7 months [range 2-5 years]) with CP due to hypoxic-ischemic encephalopathy, stroke, or periventricular leukomalacia were randomized to three arms: (1) the AlloCB group received 10 × 107 AlloCB total nucleated cells (TNC) per kilogram at baseline (n = 31); (2) the hCT-MSC group received 2 × 106 hCT-MSC at baseline, 3 months, and 6 months (n = 28); (3) the natural history control group received 10 × 107 AlloCB TNC per kilogram at 12 months (n = 31). Motor function was assessed with the Gross Motor Function Measure-66 (GMFM-66) and Peabody Developmental Motor Scale, Second Edition. RESULTS: Infusions (n = 143) were well tolerated, with eight infusion reactions (three in the AlloCB group, five in hCT-MSC) and no other safety concerns. At 12 months, the mean differences (95% confidence intervals [CI]) between actual and expected changes in GMFM-66 score were AlloCB 5.8 points (3.4-8.2), hCT-MSC 4.3 (2.2-6.4), and natural history 3.1 (1.4-5.0). In exploratory, post hoc analysis, the mean GMFM-66 score (95% CI) of the hCT-MSC group was 1.4 points higher than natural history (-1.1 to 4.0; p = 0.27), and the AlloCB group was 3.3 points higher than natural history (0.59-5.93; p = 0.02) after adjustment for baseline Gross Motor Function Classification System level, GMFM-66 score, and etiology. INTERPRETATION: High-dose AlloCB is a potential cell therapy for CP and should be further tested in a randomized, blinded, placebo-controlled trial. WHAT THIS PAPER ADDS: Unrelated donor allogeneic umbilical cord blood (AlloCB) and human umbilical cord tissue-derived mesenchymal stromal cell infusion is safe in young children with cerebral palsy. Significant changes in motor function were not observed 6 months after treatment. One year later, treatment with AlloCB was associated with greater increases in Gross Motor Function Measure-66 scores.
Authors
Sun, JM; Case, LE; McLaughlin, C; Burgess, A; Skergan, N; Crane, S; Jasien, JM; Mikati, MA; Troy, J; Kurtzberg, J
MLA Citation
Sun, Jessica M., et al. “Motor function and safety after allogeneic cord blood and cord tissue-derived mesenchymal stromal cells in cerebral palsy: An open-label, randomized trial.Dev Med Child Neurol, vol. 64, no. 12, Dec. 2022, pp. 1477–86. Pubmed, doi:10.1111/dmcn.15325.
URI
https://scholars.duke.edu/individual/pub1526177
PMID
35811372
Source
pubmed
Published In
Dev Med Child Neurol
Volume
64
Published Date
Start Page
1477
End Page
1486
DOI
10.1111/dmcn.15325

Expanded Access Protocol of Umbilical Cord Blood Infusion for Children with Neurological Conditions: An Update.

Authors
McLaughlin, C; West, T; Hollowell, R; Skergan, N; Giguere, P; Vinesett, R; Arbuckle, E; Cash, J; Hoyle, K; Crane, S; Moore, L; Waters-Pick, B; Hawkins, T; Prasad, V; Sun, J; Kurtzberg, J
MLA Citation
McLaughlin, Colleen, et al. “Expanded Access Protocol of Umbilical Cord Blood Infusion for Children with Neurological Conditions: An Update.Stem Cells Transl Med, vol. 10, no. S1, Sept. 2021, pp. S7–8. Pubmed, doi:10.1002/sct3.13016.
URI
https://scholars.duke.edu/individual/pub1521970
PMID
35599372
Source
pubmed
Published In
Stem Cells Transl Med
Volume
10
Published Date
Start Page
S7
End Page
S8
DOI
10.1002/sct3.13016

DTI Tract-Based Quantitative Susceptibility Mapping: An Initial Feasibility Study to Investigate the Potential Role of Myelination in Brain Connectivity Change in Cerebral Palsy Patients During Autologous Cord Blood Cell Therapy Using a Rotationally-Invar

BACKGROUND: Previous studies using diffusion tensor imaging (DTI)-based connectome analysis revealed improved connectivity in cerebral palsy (CP) patients who underwent autologous umbilical cord blood (UCB) stem-cell therapy. However, the potential mechanism for the connectivity increase remains unclear and needs to be further elucidated. PURPOSE: To develop a technique with improved accuracy for quantitative susceptibility mapping (QSM) with unique sensitivity to myelin, and demonstrate its use in elucidating the underlying mechanism of the observed motor function improvement and brain connectivity increase in CP patients who received autologous UCB stem-cell therapy. STUDY TYPE: Prospective. POPULATION: A cohort of eight pediatric CP patients (2.6 ± 0.6 years of age) with intact corticospinal tracts (CST) from a randomized, placebo-controlled trial of autologous UCB stem-cell therapy in CP children was included in this study. FIELD STRENGTH/SEQUENCE: DTI and 3D spoiled gradient recalled (SPGR) QSM at 3.0T. ASSESSMENT: Pre- and posttreatment magnetic susceptibility (χ) and the rotationally-invariant magnetic susceptibility anisotropy (MSA) along the CST were derived. Behavioral changes were assessed using the 66-item Gross Motor Function Measurement. Changes in χ and MSA were compared between patients with and without substantial behavioral improvements. STATISTICAL TESTS: Two-sample t-tests were performed to assess the differences in the changes of measurements of interest (Δχ, ΔMSA, and ΔFA) between patients who significantly improved and those who did not. RESULTS: Patients who demonstrated posttreatment motor improvements exceeding expectations showed significantly more diamagnetic Δχ in the periventricular region along the CST (P = 0.003). Further analysis on the ΔMSA of this region was significantly increased (P = 0.006) for high responders, along with concurrent FA increase. DATA CONCLUSION: These initial findings suggest that the DTI tract-based QSM method has the potential to characterize white matter changes associated with behavioral improvements in CP children who underwent cord blood stem-cell therapy. LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY: Stage 2.
Authors
Zhang, L; Ellor, S; Sun, JM; Liu, C; Kurtzburg, J; Song, AW
URI
https://scholars.duke.edu/individual/pub1452091
PMID
32677156
Source
pubmed
Published In
J Magn Reson Imaging
Volume
53
Published Date
Start Page
251
End Page
258
DOI
10.1002/jmri.27286

Novel intronic DICER1 variation associated with pleuropulmonary blastoma in two siblings.

Pleuropulmonary blastomas (PPB) are rare aggressive paediatric lung malignancies associated with DICER1 variants. We present two cases, a 2-year-old girl with upper respiratory tract symptoms as well as a 6-month-old girl sibling undergoing screening due to family history of malignancy. Imaging of the 2-year-old girl revealed a large mass filling the right hemithorax which was determined to be a type II PPB after pathological examination. Imaging of the 6-month-old sibling demonstrated a small cystic lesion in the posterior basal segment of the right lower lobe which was determined to be a type 1r PPB after pathological examination. The 2-year-old girl received adjuvant chemotherapy while the baby sister underwent resection alone and both are alive and well at 12 months and 7 months, respectively. Sequence analysis in both cases confirmed the same DICER1 variation, c.2437-2A>G (likely pathogenic), which has not been previously described in the literature.
Authors
Leckey, BD; Carney, JM; Sun, JM; Pavlisko, EN
MLA Citation
Leckey, Bruce D., et al. “Novel intronic DICER1 variation associated with pleuropulmonary blastoma in two siblings.Bmj Case Rep, vol. 12, no. 1, Jan. 2019. Pubmed, doi:10.1136/bcr-2018-227391.
URI
https://scholars.duke.edu/individual/pub1367164
PMID
30665929
Source
pubmed
Published In
Bmj Case Reports
Volume
12
Published Date
DOI
10.1136/bcr-2018-227391